TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11323346
Drug: Succinylcholine (SUC)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (SUC) 1 mg/kg
Study: 12447292
Drug: Water instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water instillation (500 to 1000 mL) at the beginning of the procedure
Study: 2697729
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplementation
Study: 31382981
Drug: Cefuroxime 1500
Normalized name: cefuroxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1500 mg intravenously prior to skin incision
Study: 31382981
Drug: Cefuroxime 1500
Normalized name: cefuroxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1500 mg intravenously after clamping of the umbilical cord
Study: 29477817
Drug: Serum uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum uric acid levels >7.2 mg/dl
Study: 29477817
Drug: Serum uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum uric acid levels ≥7 mg/dl
Study: 28925134
Drug: Longxue Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longxue Tongluo capsule (two capsules each time, three times daily for 4 weeks)
Study: 28925134
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules each time, three times daily for 4 weeks)
Study: 28925134
Drug: Longxue Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longxue Tongluo capsule
Study: 23072975
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for social anxiety disorder
Study: 340390
Drug: Teorema (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teorema (210 mg/day for 21 days)
Study: 340390
Drug: Indometacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (150 mg/day for 21 days)
Study: 340390
Drug: Indometacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (75 mg/day for 21 days)
Study: 21747013
Drug: Nurse-administered behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered behavioral management
Study: 21747013
Drug: Nurse- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse- and physician-administered medication management
Study: 16393297
Drug: Laxative (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative (polyethylene glycol 3350 oral solution)
Study: 16393297
Drug: Laxative and
Normalized name: DOCUSATE SODIUM 50 mg / SENNOSIDES 8.6 mg ORAL TABLET [Laxative and Stool Softener]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative and tegaserod
Study: 10193418
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy initiation
Study: 8525072
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (triamcinolone 200 mg i.v. within 4 h after trauma, followed by 3 x 40 mg/day i.v. for 4 days, and 3 x 20 mg/day i.v. for a further 4 days)
Study: 8525072
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (injections without active drug)
Study: 8525072
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (in patients with focal lesion and Glasgow Coma Score < 8)
Study: 6989226
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) users
Study: 6989226
Drug: Sucrose load
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose load (1 g/kg)
Study: 6989226
Drug: Peak levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak levels of glucose and insulin
Study: 26329790
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg (day 1)
Study: 19085343
Drug: Aliskiren/HCT 300/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/HCT 300/25 mg
Study: 17342794
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (child's usual treatment)
Study: 22763312
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib
Study: 3178925
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol
Study: 31164265
Drug: Letrozole (L)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (L)
Study: 22712469
Drug: DHEA replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA replacement therapy (50 mg day(-1))
Study: 16632234
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin sliding scale
Study: 12810472
Drug: Intranasal furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal furosemide
Study: 12810472
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate
Study: 8979159
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement of ascorbate, alpha‐tocopherol and beta‐carotene
Study: 1350882
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitrate therapy (patch removed at night, mean patch-off period 10 hours)
Study: 1350882
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal nitrate therapy (10 mg/24 hours)
Study: 22714699
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 (monoclonal antibody inhibitor of PCSK9)
Study: 20624650
Drug: Subcutaneous mite
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP)
Study: 20624650
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) therapy alone
Study: 12088809
Drug: 1.0 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 L/min fresh gas flow
Study: 12088809
Drug: 2.0 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 L/min fresh gas flow
Study: 2616932
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A followed by Treatment B
Study: 2616932
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B followed by Treatment A
Study: 319967
Drug: Pimozide 9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide 9.6 mg
Study: 319967
Drug: Fluphenazine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 12.5 mg
Study: 30138668
Drug: Dupilumab 200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200/300 mg every 2 weeks
Study: 18591555
Drug: Topotecan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2) on day 1 and 600 mg/m(2) on day 8 every 3 weeks
Study: 15982747
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day (increased to 20 mg/day after 4 weeks)
Study: 17288677
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day
Study: 12162936
Drug: Combined ACE
Normalized name: ACE INHIBITORS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ACE inhibitor plus ARB therapy
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents with antiplatelet drugs (250 mg ticlopidine and 100 mg aspirin)
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents in phase I
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents in phase II
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents in phase III
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents in phase IV
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents (all phases combined)
Study: 8565157
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents (phase I)
Study: 27494705
Drug: Multisystemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy
Study: 20015219
Drug: Intermittent interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART)
Study: 17875076
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg/day) for 20 days
Study: 16132897
Drug: Parenteral lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral lipid‐based nutrition (L group)
Study: 16132897
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral glucose‐based nutrition (G group)
Study: 2112080
Drug: Chinese-made levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese-made levonorgestrel tablets (0.75 mg)
Study: 7323106
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg intramuscular procaine penicillin daily for 14 days
Study: 7323106
Drug: 1080 mg
Normalized name: magaldrate 1080 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1080 mg intramuscular procaine penicillin daily for 14 days
Study: 7323106
Drug: 1440 mg
Normalized name: ZINC OXIDE 1440 mg in 8 g TOPICAL POWDER [bareMinerals Original Foundation Broad Spectrum SPF 15 Deepest Deep 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1440 mg intramuscular procaine penicillin daily for 14 days
Study: 28390934
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine (IIV4)
Study: 31426731
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg for 6 months
Study: 29079602
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual supplemented by a booklet on self-management
Study: 26475266
Drug: TRK-100STP 120
Normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK-100STP 120 μg/day
Study: 26475266
Drug: TRK-100STP 240
Normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK-100STP 240 μg/day
Study: 22111658
Drug: Alfentanil 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 7.5 μg/kg
Study: 20184225
Drug: Triflusal oral
Normalized name: triflusal Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal oral solution (600 mg)
Study: 21327422
Drug: Triflusal capsules
Normalized name: triflusal
DrugBank: Triflusal (DB08814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal capsules (600 mg)
Study: 19736358
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control (WLC) plus treatment as usual
Study: 10437612
Drug: Adjuvant intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant intra-arterial chemotherapy (mitomycin C 8 mg/m2 on day 1 and 5-fluorouracil 800 mg/m2 on days 1-5 for four courses at 4-week intervals) in group A (14 patients)
Study: 19256155
Drug: Lactitol (LA)
Normalized name: Lactitol
DrugBank: Lactitol (DB12942)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactitol (LA) 29 g/day
Study: 12734151
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug three times a day for two weeks before surgery
Study: 12734151
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg) three times a day for two weeks before surgery
Study: 29737805
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement containing Lactobacillus acidophilus LA‐5, Bifidobacterium BB‐12, Streptococcus Thermophilus STY‐31, and Lactobacillus delbrueckii bulgaricus LBY‐27
Study: 27689551
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS (2 mA for 20 minutes) + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Study: 27689551
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Study: 22227576
Drug: CHESS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHESS plus therapy
Study: 20357371
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 1.5 units/kg
Study: 20357371
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 1.0 units/kg
Study: 16043735
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg OD) + Metformin (1.5-3.0 mg/day)
Study: 16043735
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Metformin (1.5-3.0 mg/day)
Study: 31179546
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (three doses: 0, 2, 6 months)
Study: 26935044
Drug: Chloroquine 250
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 250 mg orally for the first 12 weeks
Study: 15763039
Drug: Description of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description of a treatment as new
Study: 15763039
Drug: Doctor's uncertainty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor's uncertainty about the best treatment
Study: 9713140
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg, single dose)
Study: 31461575
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy
Study: 24176804
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy‐cognitive
Study: 24176804
Drug: Pre‐treatment AS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐treatment AS dimensions
Study: 12924753
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg)
Study: 16685054
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (20 mg/d)
Study: 9625272
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg [14C]-labelled Losigamone
Study: 9625272
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of each of the unlabelled enantiomers
Study: 16338269
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers
Study: 24298801
Drug: Modified step‐back
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified step‐back technique with Gates‐Glidden bur (Group G)
Study: 10436310
Drug: Low-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose n-3 fatty acids (330 mg/day docosahexaenoic acid and 630 mg/day eicosapentanoic acid)
Study: 7788823
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (OND) 0.1 mg.kg-1
Study: 7788823
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (OND)
Study: 2177861
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 UI twice daily
Study: 15653010
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 80 mg twice daily for 12 months
Study: 10660871
Drug: Maltodextrin (CHO)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (CHO) at a dosage of 0.7 g.kg body mass‐1
Study: 8403177
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral diazepam
Study: 21148030
Drug: cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinacalcet plus low‐dose vitamin D sterols (30‐180 mg/day and ≤ 2 μg paricalcitol equivalent/dialysis)
Study: 21148030
Drug: flexible vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flexible vitamin D therapy
Study: 17715422
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (6 mg/24 h)
Study: 19527191
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (12 mg/24 h)
Study: 19527191
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (6 mg/24 h and 12 mg/24 h)
Study: 12225701
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ethanol
Study: 9447863
Drug: Physostigmine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.04 mg/kg)
Study: 30643009
Drug: Meperidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.5 mg/kg)
Study: 8523623
Drug: Oxandrolone (OX)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (OX) plus a high caloric food supplement
Study: 2191938
Drug: Nimodipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (10-20 mg t.i.d., according to body weight)
Study: 375121
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g L-dopa + 200 mg carbodopa + 300 mg imipramine orally for 30 days
Study: 375121
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg apomorphine s.c. + 2 g L-dopa + 200 mg carbodopa per os daily for 15 days
Study: 31351492
Drug: Modified minimally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified minimally invasive surgical therapy (M-MIST)
Study: 29771062
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray with 2.3% hypertonic saline
Study: 2908300
Drug: Carvedilol 25mg
Normalized name: CARVEDILOL 25MG TAB
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 25mg twice daily
Study: 2908300
Drug: Metoprolol 50mg
Normalized name: HCTZ 25/METOPROLOL 50MG TAB
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 50mg twice daily
Study: 24360050
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) 0.3 µg/kg intravenously for initial bolus (duration 15 min) and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Study: 24360050
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) 0.5 µg/kg intravenously (duration 15 min) for initial load and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Study: 12759560
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg triazolam (TRZ)
Study: 3510286
Drug: Dexamethasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (50 mg IV bolus on admission, then 100 mg on Days 1, 2, and 3, 50 mg on Day 4, and 25 mg on Day 5 on continuous IV infusion)
Study: 26882043
Drug: VTP-27999 (75-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTP-27999 (75-600 mg)
Study: 22313154
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg once daily for 24 weeks
Study: 17563091
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of long-acting benzodiazepines (restricted to subjects with four or less prescriptions filled in the previous year)
Study: 16154346
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ephedrine 30 mg in 1 L of 0.9% saline after spinal block, titrated to maternal systolic pressure.
Study: 16154346
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L 0.9% saline before spinal block (control group).
Study: 12012141
Drug: Topotecan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan alone (1.5 mg/m² for 5 days)
Study: 12012141
Drug: Topotecan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan with amifostine (300 mg/m² prior to topotecan)
Study: 1486827
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg Zopiclone
Study: 22453200
Drug: Progesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (300 mg daily at bedtime)
Study: 18027874
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg injection)
Study: 12456421
Drug: Ketamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (various doses)
Study: 2344010
Drug: Bromocriptine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine treatment for four months
Study: 21525141
Drug: Dioctahedral smectite
Normalized name: Dioctahedral smectite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctahedral smectite (DS) 1.5 g thrice daily for 5 days
Study: 17845320
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate for maximum of 48 h
Study: 21262883
Drug: NIPPV (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPPV (in infants who received surfactant therapy)